Preclinical evaluation of the HSP90 inhibitor SNX-5422 in Ibrutinib-resistant CLL has furthermore been described, and destabilization of ROR1 enhances the activity of Ibrutinib against CLL in vivo [64,157]. The gene discussed is HSP90AB1; the disease is B-cell chronic lymphocytic leukemia.